Analiza nivoa insulinske rezistencije u pacijenata sa tipom I dijabetesa
Sažetak
Uvod: Brojne dosadašnje studije utvrdile su prisustvo insulinske rezistencije (IR) kod tipa 1 dijabetesa (T1D), zarad čije procene se određuje procenjena stopa preuzimanja glukoze (estimated glucose disposal rate- eGDR).
Cilj rada: Analiza nivoa IR u pacijenata sa T1D i poređenje prema prisustvu hroničnih komplikacija dijabetesa.
Materijal i metode: Istraživanje je rađeno u formi retrospektivne analize baze podataka medicinske dokumentacije 180 pacijenata oba pola sa T1D, dužine trajanja bolesti veće od godinu dana u periodu 2016- 2021. godine, koji su na osnovu nivoa eGDR podeljeni u dve grupe- IRG (N= 86, eGDR< 8) i ISG (N= 94, eGDR≥ 8).
Rezultati: Ustanovili smo da su pacijenti iz IRG bili statistički značajnije starije životne dobi (39,35 ± 1,39 vs. 32,13 ± 0,90, p< 0,01), višeg ITM (25,93 ± 0,59 vs. 21,78 ± 0,36 kg/ m2, p< 0,01), nivoa HbA1c (9,63 ± 0,24 vs. 8,30 ± 0,15 %, p< 0,01) i dnevne doze insulina (46,51 ± 1,89 vs. 35,89 ± 1,34 j/ dan, p< 0,01) u poređenju sa pacijentima iz ISG. Istovremeno, pacijenti IRG su imali značajno viši nivo holesterola (4,97 ± 0,14 vs. 4,51 ± 0,10 mmol/l, p< 0,01), LDL-a (2,97 ± 0,13 vs. 2,51 ± 0,09 mmol/l, p< 0,01) i tgc (1,65 ± 0,16 vs. 1,01 ± 0,06 mmol/l, p< 0,01) u poređenju sa ISG. U IRG je statistički značajno veći procenat hipertenzije (97,27 vs. 2,73 %, p< 0,01), retinopatije (25,83 vs. 14,57%, p< 0,01), neuropatije (31,79 vs. 25,16 %, p= 0,021) i nefropatije (27,03 vs. 12,16%, p< 0,01) u poređenju sa ISG.
Zaključak: Pacijenti sa T1D i IR bili su starije životne dobi, viših vrednosti ITM, HbA1c, dnevne doze insulina, sa aterogenijim lipidnim profilom, većom učestalošću hipertenzije, češćim mikrovaskularnim i makrovaskularnim komplikacijama.
Ključne reči: T1D, IR, kardiovaskularni rizik, eGDR
Reference
1. DeFronzo RA, Simonson D, Ferrannini E. Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulindependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1982;23:313–319
2. DeFronzo RA, Hendler R, Simonson D. Insulin resistance is a prominent feature of insulin-dependent diabetes. Diabetes 1982;31:795–801
3. Chillarón JJ, Flores-Le-Roux JA, Goday A, et al. Metabolic syndrome and type-1 diabetes mellitus: prevalence and associated factors. Rev Esp Cardiol 2010;63:423– 429 [in Spanish]
4. Thorn LM, Forsblom C, Fagerudd J, et al; FinnDiane Study Group. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 2005;28:2019–2024
5. Rodrigues TC, Canani LH, Gross JL. Metabolic syndrome, insulin resistance and cardiovascular disease in type-1 diabetesmellitus. Arq Bras Cardiol 2010;94: 134–139 [in Portuguese]
6.Martin FIR, Stocks AE: Insulin sensitivity and vascular disease in insulin-dependent diabetes. Br Med J 2:81–82, 1968
7. Martin FIR, Warne GL: Factors influencing the prognosis of vascular disease in insulin-deficient diabetics of long duration: a seven-year follow-up. Metabolism 24:1–9, 1975
8. Martin FIR, Hopper JL: The relationship of acute insulin sensitivity to the progression of vascular disease in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia 30:149–153, 1987
9. Yip J, Mattock MB, Morocutti A, Sethi M, Trevisan R, Viberti GC: Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet 342:883–887, 1993
10. DeFronzo RA and Del Prato S. Insulin resistance and diabetes mellitus. J Diabetes Complications 1996; 10: 243–245.
11. Kietsiriroje N, Pearson S, Campbell M, et al. Double diabetes: a distinct high-risk group? Diabetes Obes Metab 2019; 21: 2609–2618.
12. Shi Y and Vanhoutte PM. Macro- and microvascular endothelial dysfunction in diabetes. J Diabetes 2017; 9: 434–449.
13. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237(3):E214-223.
14. Nystrom T, Holzmann MJ, Eliasson B, Svensson A-M, Sartipy U. Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes. Diabetes Obes Metab. 2018;20(3):556–563.
15. Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 2000;49:626–632
16. Epstein EJ, Osman JL, Cohen HW, Rajpathak SN, Lewis O, Crandall JP (2013) Use of the estimated glucose disposal rate as a measure of insulin resistance in an urban multiethnic population with type 1 diabetes. Diabetes Care 36(8):2280–2285.
17. Chillarón JJ, Goday A, Flores-Le-Roux JA, et al. Estimated glucose disposal rate in assessment of the metabolic syndrome and microvascular complications in patients with type 1 diabetes. J Clin Endocrinol Metab 2009;94:3530– 3534
18. Zheng X, Huang B, Luo S, et al. A new model to estimate insulin resistance via clinical parameters in adults with type 1 diabetes. Diabetes Metab Res Rev 2017; 33.
19. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173–194, 1991
20. Reaven GM: The role of insulin resistance and hyperinsulinemia in coronary heart disease. Metabolism 41:16–19, 1992
21. Depres J, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952–957, 1996
22. Reaven GM: Insulin resistance and its consequences: non-insulin-dependent diabetes mellitus and coronary heart disease in Diabetes Mellitus: A Fundamental and Clinical Text. LeRoith D, Taylor SI, Olefsky JM, Eds. Philadelphia, Lippincott-Raven, 1996, p. 509–518
23. Donga E, Dekkers OM, Corssmit E, Romijn JA (2015) Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: systematic review and meta-analysis. Eur J Endocrinol 173(1):101–109
24. Schauer IE, Snell-Bergeon JK, Bergman BC, Maahs DM, Kretowski A, Eckel RH, Rewers M (2011)
Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: the CACTI study. Diabetes 60(1):306–314
25. Chaturvedi N, Sjoelie A-K, Porta M, Aldington SJ, Fuller JH, Songini M, Kohner EM (2001) Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes: the EURODIAB prospective complications study. Diabetes Care 24(2):284–289
26. Makinen V-P, Forsblom C, Thorn LM, Waden J, Gordin D, Heikkila O, Hietala K, Kyllonen L, Kyto J, Rosengard-Barlund M (2008) Metabolic phenotypes, vascular complications, and premature deaths in a population of 4,197 patients with type 1 diabetes. Diabetes 57(9):2480–2487
27. Stuhldreher WL, Becker DJ, Drash AL, Ellis D, Kuller LH, Wolfson SK, Orchard TJ: The association of waist/hip ratio with diabetes complications in an adult IDDM population. J Clin Epidemiol 47:447–456, 1994
28. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK, Ferrannini E: Parental history of diabetes is associated with increased cardiovascular risk factors. Arteriosclerosis 9:928–933, 1989
29. Ishikawa M, Pruneda ML, Adams-Huet B, Raskin P: Obesity-independent hyperinsulinemia in nondiabetic first-degree relatives of individuals with t y p e 2 diabetes. Diabetes 47:788–792, 1998
30.Wingard DL, Barrett-Connor E: Family history of diabetes and cardiovascular risk factors and mortality among euglycemic, borderline hyperglycemic, and diabetic adults. Am J Epidemiol 125:948–958, 1987
31. Eddy D, Schlessinger L, Kahn R, Peskin B, Schiebinger R. Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysis. Diabetes Care. 2009;32(2):361-6.
32. Orchard TJ, Chang Y-F, Ferrell RE, Petro N, Ellis DE (2002) Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int 62(3):963–970
33. Olson JC, Erbey JR, Forrest KY, Williams K, Becker DJ, Orchard TJ (2002) Glycemia (or, in women, estimated glucose disposal rate) predict lower extremity arterial disease events in type 1 diabetes. Metabol Clin Exp 51(2):248–254
34. Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY-Z, Kinder LS, Ellis D, Becker DJ (2003) Insulin resistance–related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications study. Diabetes Care 26(5):1374–137
35. Pambianco G, Costacou T, Orchard TJ (2007) The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care 30(5):1248–1254